PureTech Health (LON:PRTC) Hits New 12-Month Low – Should You Sell?

PureTech Health plc (LON:PRTC)’s share price reached a new 52-week low on Thursday . The stock traded as low as GBX 123.20 ($1.59) and last traded at GBX 135.40 ($1.75), with a volume of 26766676 shares changing hands. The stock had previously closed at GBX 127.20 ($1.65).

Analysts Set New Price Targets

Separately, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 455 ($5.89) price objective on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Price Performance

The company has a market capitalization of £442.16 million, a price-to-earnings ratio of -6.04 and a beta of 1.02. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The company’s 50 day simple moving average is GBX 139.75 and its 200-day simple moving average is GBX 149.81.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.